Barrett’s Esophagus is associated with long-term gastro-esophageal reflux disease (GERD) and is a risk factor for esophageal cancer. Current practice is to screen select patients who have multiple risk factors for esophageal cancer and monitor those patients diagnosed with Barrett's Esophagus for development of precancerous change (dysplasia). Patients who are at higher risk of progressing to esophageal cancer may benefit from endoscopic therapy.
ISDE endorsed and sponsored the following research:
- 2015 International Consensus of the Management of Benign Barrett’s (BOB CAT)
- 2012 Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process (BAD CAT)
Additional information can be found below.
- Prague classification of Barrett’s esophagus
- 2018 and 2012 guidelines from the American Society of Gastrointestinal Endoscopy
- 2016 guideline from the American College of Gastroenterology
- 2014 guideline from the British Society of Gastroenterology
- 2016 expert review and 2011 guideline from the American Gastroenterological Association